Clinical Trials | June 02, 2026
STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial
While overall survival data remain immature, the results pointed to a favourable trend.
While overall survival data remain immature, the results pointed to a favourable trend.
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
The company is building a connected healthcare ecosystem that utilises smart healthcare kiosk and mobile app to deliver at-home, AI-assisted health screenings and non-invasive health measurements
The therapy also delivered significant improvements in key liver enzyme markers
This marks one of the most closely watched oncology readouts at this year’s medical congress
The company plans to establish similar healthcare centres across universities, schools, and corporate campuses nationwide
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
